Gedatolisib is a dual PI3K/mTOR inhibitor, and levels of mRNAs encoding HPRT1 (a key component of the purine rescue pathway) differ significantly between non-small cell lung cancer cells that are sensitive or resistant to gedatolisib. This evidence concerns the gene HPRT1 and non-small cell lung carcinoma.